In an expert view piece, Jim Sykes, sector managing director for pharmaceutical and life sciences at global talent acquisition and management firm, Alexander Mann Solutions, considers current risks of losing skilled personnel and how these can be addressed.
Suffice it to say, 2016 was a year of incredible political, economic and environmental change. It is clear that there are massive shifts in power occurring around the globe, and not one industry will be spared the impact of these potentially seismic shifts.
For the pharmaceutical industry in the UK, many historical struggles look set to worsen. Ongoing cuts in government spending, patent cliffs, and shifts in business focus between therapeutic areas are all threatening the stability of the sector, but Brexit could exacerbate this.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze